Group 1 - The company has approved the 2025 Restricted Stock Incentive Plan and disclosed the list of incentive objects [1][2] - The public notice regarding the incentive objects was conducted from August 25, 2025, to September 3, 2025, with no objections received [2][4] - The Compensation and Assessment Committee verified the qualifications of the proposed incentive objects, confirming compliance with relevant laws and regulations [2][4] Group 2 - The verification process included checking the identity documents, employment contracts, and positions held by the proposed incentive objects [2][4] - The committee concluded that all proposed incentive objects meet the necessary qualifications as per the Company Law and Securities Law [3][4] - The incentive plan includes only employees with labor or employment relationships with the company, excluding independent directors [4]

Core Viewpoint - Shanghai Sanyou Medical Devices Co., Ltd. will participate in the 2025 semi-annual performance briefing for the medical device industry organized by the Shanghai Stock Exchange, aiming to enhance communication with investors [1][2]. Group 1: Meeting Details - The meeting is scheduled for September 17, 2025, from 15:00 to 17:00 [1][2]. - It will be held at the Shanghai Stock Exchange Roadshow Center and conducted in an online interactive format [1][2]. - Investors can submit questions from September 10 to September 16, 2025, before 16:00 [1][3]. Group 2: Participants - Key participants include Chairman and Chief Scientist Michael Mingyan Liu, President Xu Nong, Vice President and Secretary David Fan, Financial Director Ni Nuan, and Independent Director Gu Shaoyu [2]. Group 3: Investor Participation - Investors can join the briefing online via the Shanghai Stock Exchange Roadshow Center on the day of the event [2][3]. - The company will address commonly asked questions during the session [2].

Core Viewpoint - The company has announced the establishment of a special account for raised funds and signed a tripartite supervision agreement for the management of these funds, aimed at ensuring compliance with regulations and protecting investor interests [1][5]. Fundraising Overview - The company approved the temporary use of up to 90 million yuan of idle raised funds to supplement working capital, with a usage period not exceeding 12 months from the board's approval date [2]. - The company raised a total of 1,075,950,160 yuan from its initial public offering (IPO) by issuing 51,333,500 shares at a price of 20.96 yuan per share, with a net amount of 978,892,778.72 yuan after deducting issuance costs [2][3]. - Additionally, the company raised 203,920,127.60 yuan through a share issuance for asset acquisition, issuing 13,032,886 shares at a price of 16.42 yuan per share, after deducting related issuance costs [3][4]. Special Account and Supervision Agreement - A special account has been opened at Shanghai Pudong Development Bank for the storage of temporarily supplemented working capital, with a tripartite supervision agreement signed between the company, the bank, and the financial advisor, Dongfang Securities [5][6]. - The agreement stipulates that the funds in the special account are exclusively for temporary working capital and cannot be used for other purposes [6][7]. - The financial advisor is responsible for supervising the use of the raised funds and must conduct regular checks and provide monthly account statements to the company [6][8]. Compliance and Legal Framework - The agreement is governed by relevant laws and regulations, including the Company Law and the Securities Law of the People's Republic of China, ensuring that all parties adhere to legal requirements [8][9]. - Any disputes arising from the agreement will be resolved through negotiation or arbitration in Shanghai, with the arbitration ruling being final and binding [9].

证券代码：688085 证券简称：三友医疗 公告编号：2025-066 上海三友医疗器械股份有限公司 董事会薪酬与考核委员会 关于公司 2025 年限制性股票激励计划激励对象名单 的核查意见及公示情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、公示情况及核查方式 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）及《上海三友医疗器械股份有限公司章程》（以下简称"《公司章程》"） 的相关规定，公司对拟激励对象名单在公司内部进行了公示。公司董事会薪酬与 考核委员会结合公示情况对拟激励对象人员名单进行了核查，相关公示情况及核 查情况如下： 1、公司对拟激励对象的公示情况 （1）公示内容：拟激励对象姓名及职务 （2）公示时间：2025 年 8 月 25 日至 2025 年 9 月 3 日，共 10 日 （3）公示方式：公司内部布告栏 （4）反馈方式：以设立反馈电话/电子邮箱或当面反映情况等方式进行反馈， ...

东方证券股份有限公司 部分限售股上市流通的核查意见 东方证券股份有限公司（以下简称"独立财务顾问"或"东方证券"）作为 上海三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"）发行股份 及支付现金购买资产并募集配套资金暨关联交易的独立财务顾问，根据《上市后 公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管理办法》《上海 证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》等法律法规的相关规定，对三友医疗本次部分限售股上 市流通的事项进行了专项核查，具体核查情况如下： 一、本次上市流通的限售股类型 经上海证券交易所并购重组审核委员会 2024 年 12 月 30 日审核同意，并经 中国证券监督管理委员会于 2025 年 1 月 17 日出具的《关于同意上海三友医疗器 械股份有限公司发行股份购买资产并募集配套资金注册的批复》（证监许可〔2025〕 109 号）同意上海三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"） 发行股票募集配套资金的注册申请。 公司向特定对象发行人民币普通股（A 股）股票新增 13,032,886 股股份已于 2025 ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-064 上海三友医疗器械股份有限公司 关于增设募集资金专项账户并签订募集资金专户存 储三方监管协议的公告 根据《上市公司募集资金监管规则》等法律法规的规定，为规范公司募集资 金的管理和使用，保护投资者的权益，2025 年 8 月 22 日召开的公司第四届董事 会第二次会议审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议 案》，同意公司开立募集资金专项账户，仅用于存放暂时补充流动资金的募集资 金，与保荐机构/独立财务顾问、募集资金存放银行签署募集资金专项存储监管 协议，并严格按照《上市公司募集资金监管规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》以及公司《募集资金管理制度》等有关 规定实施监管。公司董事会授权公司经营管理层办理闲置募集资金暂时补充流动 资金募集资金专项账户的开立，并与保荐机构/独立财务顾问、存放募集资金的 商业银行签署相关监管协议等事宜。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海三友医疗器械股份有限 ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-065 上海三友医疗器械股份有限公司 发行股份及支付现金购买资产并募集配套资金 暨关联交易之部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为向特定对象发行股份；股票认购方式为网下，上市股 数为15,639,463股。 本次股票上市流通总数为15,639,463股。 本次股票上市流通日期为2025 年 9 月 15 日。（因 2025 年 9 月 13 日是非 交易日，上市流通日顺延至 2025 年 9 月 15 日） 一、本次上市流通的限售股类型 本次上市流通的限售股为公司因发行股份募集配套资金向特定对象发行的限 售股，涉及股东 10 名，该部分限售股股东对应的股份数量为 15,639,463 股，锁 定期为自发行结束之日起 6 个月。本次申请上市流通的限售股 15,639,463 股，占 公司股份总数的 4.69%，将于 2025 年 9 月 15 日解除限售并上市流通（因 2025 年 9 月 13 ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-067 上海三友医疗器械股份有限公司 重要内容提示： （网址：http://roadshow.sseinfo.com/） 为进一步加强与广大投资者的沟通交流，上海三友医疗器械股份有限公 司（以下简称"公司"）将参加由上海证券交易所主办的 2025 年半年度科创 板医疗器械及医疗设备行业集体业绩说明会，现将有关事项公告如下： 1 会议召开时间：2025 年 9 月 17 日（星期三） 下午 15:00-17:00 会议召开地点：上海证券交易所上证路演中心 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 9 月 10 日（星期三）至 9 月 16 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sanyou-medical.com 进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 公司已于 2025 年 8 月 26 日在上海证券交易所网站（www.sse.com.cn） 披露公司《2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状 ...

Core Insights - The Chinese medical device industry faced challenges and opportunities in the first half of 2025, with a recovery in bidding for medical equipment not yet translating into improved company performance [1][3] - Overall performance of the industry remained under pressure due to complex global macroeconomic conditions, with a decline in revenue and net profit for A-share medical device companies [1][3] Financial Performance - In the first half of 2025, 131 A-share medical device companies reported total revenue of 1188.17 billion yuan, a decrease of 4.29% from 1241.43 billion yuan in the previous year [1] - Net profit for these companies fell to 188.12 billion yuan, down 17.17% from 227.11 billion yuan year-on-year [1] - Over 80% of companies in the in vitro diagnostics sector experienced a decline in performance due to factors like centralized procurement and medical insurance cost control [1] Sector Highlights - Despite overall declines, certain sectors like orthopedics and cardiovascular devices showed significant growth, with companies such as Sanyou Medical and Dabo Medical reporting revenue growth exceeding 40% [1][4] - Sanyou Medical achieved a remarkable net profit growth of 2083.64%, driven by acquisitions and recovery in domestic business [4] International Market Expansion - Overseas markets have become crucial for leading companies to overcome growth bottlenecks, with companies like Ruimai Te and Yuyue Medical reporting revenue growth of 61.33% and 49.96% respectively from international sales [2][7] - The international revenue for 89 companies reached 332.47 billion yuan, marking an 8.2% increase year-on-year [6] Future Outlook - The industry anticipates a turning point in the second half of 2025, with signs of demand recovery and improved bidding activity for medical devices [3][10] - The approval of innovative medical devices and drugs is on the rise, with 45 innovative medical devices approved in the first half of 2025, a year-on-year increase of 87% [12][13]

从资金流向上来看，当日医疗器械板块主力资金净流出4.57亿元，游资资金净流出2.07亿元，散户资金净 流入6.64亿元。医疗器械板块个股资金流向见下表： 证券之星消息，9月4日医疗器械板块较上一交易日下跌1.92%，三友医疗领跌。当日上证指数报收于 3765.88，下跌1.25%。深证成指报收于12118.7，下跌2.83%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 835892 | 中科美菱 | 25.80 | 15.85% | 15.32万 | 3.85亿 | | 603222 | 济民健康 | 11.52 | 10.03% | 34.43万 | 3.90亿 | | 688656 | 浩欧博 | 132.54 | 6.45% | < 3.98万 | 5.29亿 | | 300753 | 爰朋医疗 | 34.60 | 6.13% | 16.94万 | 5.79亿 | | 836504 | 博讯生物 | 29.88 | 4.18% | 1.37万 | 4076 ...